Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion

Transplantation

Volumn 76, Issue 6, 2003, Pages 903-908

  Thervet, Eric ^a   Pfeffer, Per ^b   Scolari, Maria Piera ^c   Toselli, Lorenzo ^d   Pallardó, Luis M ^e   Chadban, Steven ^m   Pilmore, Helen ^f   Connolly, John ^g   Buchler, Matthias ^h   Schena, Francesco Paolo ⁱ   Carreno, César Agost ^j   Dandavino, Raymond ^k   Cole, Edward ^l  

^a SAINT LOUIS HOSPITAL   (France)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d CRAI Norte   (Argentina)

^e HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^f AUCKLAND CITY HOSPITAL   (New Zealand)

^g BELFAST CITY HOSPITAL   (United Kingdom)

^h UNIVERSITY HOSPITAL OF TOURS   (France)

ⁱ UNIVERSITY OF BARI   (Italy)

^j Sanatorio Mitre   (Argentina)

^k MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^l TORONTO GENERAL HOSPITAL   (Canada)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INSULIN; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; ORAL ANTIDIABETIC AGENT; THYMOCYTE ANTIBODY;

ACUTE HEMORRHAGIC PANCREATITIS; ADULT; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; GINGIVA HYPERPLASIA; GRAFT SURVIVAL; HEART INFARCTION; HEMOLYTIC UREMIC SYNDROME; HEPATOBILIARY DISEASE; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; LIVER TOXICITY; LYMPHOCELE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MICROEMULSION; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; ORGAN TRANSPLANTATION; POLYMYOSITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL ARTERY THROMBOSIS; RHABDOMYOLYSIS; SEPSIS; TREATMENT OUTCOME; TREMOR;

ADULT; CREATININE; CYCLOSPORINE; DRUG MONITORING; EMULSIONS; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INTESTINAL ABSORPTION; KIDNEY TRANSPLANTATION; REOPERATION; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0141768209     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000089006.00653.64     Document Type: Article

References (17)

1. Pollard SG, Lear PA, Ready AR, et al. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. Transplantation 1999; 68: 1325.
2. Otto M-G, Mayer AD, Clavien P-A, et al. Randomized trial of cyclosporine microemulsion (Neoral) versus conventional cyclosporine in liver transplantation. Transplantation 1998; 66: 1632.
3. Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals or high-fat meals. Transplantation 1995; 59: 505.
4. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68(1): 55.
5. Mahalati K, Belitsky P, West K, et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol 2001; 12: 823.
6. Cantarovich M, Besner JG, Barkun JS, et al. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 1998; 12: 243.
7. 2 monitoring in pediatric liver transplant recipients. Transplant Proc 2001; 33: 3094.
8. Kelles A, Herman J, Tjandra-Maga TB, et al. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients. Pediatr Transplant 1999; 3: 282.
9. International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral®) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148.
10. max) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8). Transplantation 1999; 67: 1133.
11. International Neoral Renal Study Group. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2002; 2: 157.
12. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72: 1024.
13. 2). Transplantation 2002; 73: 953.
14. Nankivell BJ, Gruenewald SM, Allen R, et al. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683.
15. Racusen LC, Solez K, Colvin RB, et al. The Banff97 working classification of renal allograft pathology. Kidney Int 1999; 55(2): 713-723.
16. Margreiter R. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741.
17. 2 monitoring in stable renal transplant recipients may reduce cyclosporine nephrotoxicity. Transplantation 2003; 75: 2086.